Compare BioNTech SE - ADR (BNTX) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Endeavour Silver Corp — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Endeavour Silver Corp trades at $7.99 (market cap $2.39B). The key difference: BioNTech SE - ADR is far larger — about 9.6× Endeavour Silver Corp's market cap, and Endeavour Silver Corp is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | EXK | |
|---|---|---|
Market Cap | $22.86B | $2.39B |
Sector | Health | Basic Materials |
52-Week High | $119.34 | $14.12 |
52-Week Low | $83.89 | $4.96 |
Enterprise Value | $6.53B | $2.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
EXK trades at $7.84, down 2.97% on the day, amid a bearish technical signal. The company reported strong Q1 2026 results with earnings of $0.21 per share beating estimates, driven by record production. However, full-year 2025 financials show a net loss of $119.10 million. Analyst sentiment is largely positive with 11 buy ratings, but the stock faces headwinds from negative profitability metrics and high valuation multiples.
The outlook is mixed; operational improvements and silver price trends offer upside, but persistent losses and bearish technicals pose risks. Investors should weigh the company's growth potential against its current financial health and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
